APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatitis B Vaccine (Recombinant)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hepatitis B Vaccine (Recombinant) Market Analysis and Forecast 2026-2032

2 January 2026191 pages

Choose your research edition.

Industry ResearchHepatitis B Vaccine (Recombinant) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatitis B Vaccine (Recombinant) Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Hepatitis B Vaccine (Recombinant) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatitis B Vaccine (Recombinant) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatitis B Vaccine (Recombinant) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Hepatitis B Vaccine (Recombinant) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Hepatitis B Vaccine (Recombinant) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hepatitis B Vaccine (Recombinant) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hepatitis B Vaccine (Recombinant) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hepatitis B Vaccine (Recombinant) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Hepatitis B Vaccine (Recombinant) include GSK, Shenzhen Kangtai Biological Products, Merck, Serum Institute, Sanofi Pasteur, LG Life Sciences, KM Biologics and Dynavax Technologies, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Hepatitis B Vaccine (Recombinant), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hepatitis B Vaccine (Recombinant), also provides the sales of main regions and countries. Of the upcoming market potential for Hepatitis B Vaccine (Recombinant), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hepatitis B Vaccine (Recombinant) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hepatitis B Vaccine (Recombinant) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Hepatitis B Vaccine (Recombinant) sales, projected growth trends, production technology, application and end-user industry.

Hepatitis B Vaccine (Recombinant) Segment by Company

GSK

Shenzhen Kangtai Biological Products

Merck

Serum Institute

Sanofi Pasteur

LG Life Sciences

KM Biologics

Dynavax Technologies

Hepatitis B Vaccine (Recombinant) Segment by Type

10mcg/0.5ml

10mcg/ml

Hepatitis B Vaccine (Recombinant) Segment by Application

Newborn

Adult

Hepatitis B Vaccine (Recombinant) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis B Vaccine (Recombinant) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatitis B Vaccine (Recombinant) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis B Vaccine (Recombinant).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Hepatitis B Vaccine (Recombinant) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Hepatitis B Vaccine (Recombinant) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hepatitis B Vaccine (Recombinant) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hepatitis B Vaccine (Recombinant) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 10mcg/0.5ml Major Manufacturers Table 3. 10mcg/ml Major Manufacturers Table 4. Global Hepatitis B Vaccine (Recombinant) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Newborn Major Manufacturers Table 6. Adult Major Manufacturers Table 7. Hepatitis B Vaccine (Recombinant) Industry Trends Table 8. Hepatitis B Vaccine (Recombinant) Industry Drivers Table 9. Hepatitis B Vaccine (Recombinant) Industry Opportunities and Challenges Table 10. Hepatitis B Vaccine (Recombinant) Industry Restraints Table 11. Global Hepatitis B Vaccine (Recombinant) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2021-2026) Table 15. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2027-2032) Table 16. Global Hepatitis B Vaccine (Recombinant) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 17. Global Hepatitis B Vaccine (Recombinant) Sales by Region (2021-2026) & (W Units) Table 18. Global Hepatitis B Vaccine (Recombinant) Sales by Region (2027-2032) & (W Units) Table 19. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2021-2026) Table 20. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2027-2032) Table 21. Global Hepatitis B Vaccine (Recombinant) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Hepatitis B Vaccine (Recombinant) Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Manufacturers (2021-2026) Table 25. Global Hepatitis B Vaccine (Recombinant) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global Hepatitis B Vaccine (Recombinant) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Hepatitis B Vaccine (Recombinant) Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Hepatitis B Vaccine (Recombinant) Manufacturers, Product Type & Application Table 29. Global Hepatitis B Vaccine (Recombinant) Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Hepatitis B Vaccine (Recombinant) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Hepatitis B Vaccine (Recombinant) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2021-2026) Table 36. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2027-2032) Table 37. Global Hepatitis B Vaccine (Recombinant) Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 38. Global Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units) Table 39. Global Hepatitis B Vaccine (Recombinant) Sales by Type (2027-2032) & (W Units) Table 40. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2021-2026) Table 41. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2027-2032) Table 42. Global Hepatitis B Vaccine (Recombinant) Price by Type (2021-2026) & (US$/Unit) Table 43. Global Hepatitis B Vaccine (Recombinant) Price by Type (2027-2032) & (US$/Unit) Table 44. Global Hepatitis B Vaccine (Recombinant) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2021-2026) Table 48. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2027-2032) Table 49. Global Hepatitis B Vaccine (Recombinant) Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 50. Global Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units) Table 51. Global Hepatitis B Vaccine (Recombinant) Sales by Application (2027-2032) & (W Units) Table 52. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2021-2026) Table 53. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2027-2032) Table 54. Global Hepatitis B Vaccine (Recombinant) Price by Application (2021-2026) & (US$/Unit) Table 55. Global Hepatitis B Vaccine (Recombinant) Price by Application (2027-2032) & (US$/Unit) Table 56. GSK Company Information Table 57. GSK Business Overview Table 58. GSK Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. GSK Hepatitis B Vaccine (Recombinant) Product Portfolio Table 60. GSK Recent Development Table 61. Shenzhen Kangtai Biological Products Company Information Table 62. Shenzhen Kangtai Biological Products Business Overview Table 63. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product Portfolio Table 65. Shenzhen Kangtai Biological Products Recent Development Table 66. Merck Company Information Table 67. Merck Business Overview Table 68. Merck Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Merck Hepatitis B Vaccine (Recombinant) Product Portfolio Table 70. Merck Recent Development Table 71. Serum Institute Company Information Table 72. Serum Institute Business Overview Table 73. Serum Institute Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Serum Institute Hepatitis B Vaccine (Recombinant) Product Portfolio Table 75. Serum Institute Recent Development Table 76. Sanofi Pasteur Company Information Table 77. Sanofi Pasteur Business Overview Table 78. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product Portfolio Table 80. Sanofi Pasteur Recent Development Table 81. LG Life Sciences Company Information Table 82. LG Life Sciences Business Overview Table 83. LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. LG Life Sciences Hepatitis B Vaccine (Recombinant) Product Portfolio Table 85. LG Life Sciences Recent Development Table 86. KM Biologics Company Information Table 87. KM Biologics Business Overview Table 88. KM Biologics Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. KM Biologics Hepatitis B Vaccine (Recombinant) Product Portfolio Table 90. KM Biologics Recent Development Table 91. Dynavax Technologies Company Information Table 92. Dynavax Technologies Business Overview Table 93. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product Portfolio Table 95. Dynavax Technologies Recent Development Table 96. North America Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Hepatitis B Vaccine (Recombinant) Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units) Table 99. North America Hepatitis B Vaccine (Recombinant) Sales by Type (2027-2032) & (W Units) Table 100. North America Hepatitis B Vaccine (Recombinant) Sales Price by Type (2021-2026) & (US$/Unit) Table 101. North America Hepatitis B Vaccine (Recombinant) Sales Price by Type (2027-2032) & (US$/Unit) Table 102. North America Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2026) & (US$ Million) Table 103. North America Hepatitis B Vaccine (Recombinant) Revenue by Application (2027-2032) & (US$ Million) Table 104. North America Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units) Table 105. North America Hepatitis B Vaccine (Recombinant) Sales by Application (2027-2032) & (W Units) Table 106. North America Hepatitis B Vaccine (Recombinant) Sales Price by Application (2021-2026) & (US$/Unit) Table 107. North America Hepatitis B Vaccine (Recombinant) Sales Price by Application (2027-2032) & (US$/Unit) Table 108. North America Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. North America Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 110. North America Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 111. North America Hepatitis B Vaccine (Recombinant) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 112. North America Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026) & (W Units) Table 113. North America Hepatitis B Vaccine (Recombinant) Sales by Country (2027-2032) & (W Units) Table 114. North America Hepatitis B Vaccine (Recombinant) Sales Price by Country (2021-2026) & (US$/Unit) Table 115. North America Hepatitis B Vaccine (Recombinant) Sales Price by Country (2027-2032) & (US$/Unit) Table 116. United States Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 117. Canada Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 118. Europe Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2026) & (US$ Million) Table 119. Europe Hepatitis B Vaccine (Recombinant) Revenue by Type (2027-2032) & (US$ Million) Table 120. Europe Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units) Table 121. Europe Hepatitis B Vaccine (Recombinant) Sales by Type (2027-2032) & (W Units) Table 122. Europe Hepatitis B Vaccine (Recombinant) Sales Price by Type (2021-2026) & (US$/Unit) Table 123. Europe Hepatitis B Vaccine (Recombinant) Sales Price by Type (2027-2032) & (US$/Unit) Table 124. Europe Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2026) & (US$ Million) Table 125. Europe Hepatitis B Vaccine (Recombinant) Revenue by Application (2027-2032) & (US$ Million) Table 126. Europe Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units) Table 127. Europe Hepatitis B Vaccine (Recombinant) Sales by Application (2027-2032) & (W Units) Table 128. Europe Hepatitis B Vaccine (Recombinant) Sales Price by Application (2021-2026) & (US$/Unit) Table 129. Europe Hepatitis B Vaccine (Recombinant) Sales Price by Application (2027-2032) & (US$/Unit) Table 130. Europe Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Europe Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 132. Europe Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 133. Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 134. Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026) & (W Units) Table 135. Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2027-2032) & (W Units) Table 136. Europe Hepatitis B Vaccine (Recombinant) Sales Price by Country (2021-2026) & (US$/Unit) Table 137. Europe Hepatitis B Vaccine (Recombinant) Sales Price by Country (2027-2032) & (US$/Unit) Table 138. Germany Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 139. France Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 140. U.K. Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 141. Italy Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 142. Netherlands Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 143. Nordic Countries Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 144. China Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2026) & (US$ Million) Table 145. China Hepatitis B Vaccine (Recombinant) Revenue by Type (2027-2032) & (US$ Million) Table 146. China Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units) Table 147. China Hepatitis B Vaccine (Recombinant) Sales by Type (2027-2032) & (W Units) Table 148. China Hepatitis B Vaccine (Recombinant) Sales Price by Type (2021-2026) & (US$/Unit) Table 149. China Hepatitis B Vaccine (Recombinant) Sales Price by Type (2027-2032) & (US$/Unit) Table 150. China Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2026) & (US$ Million) Table 151. China Hepatitis B Vaccine (Recombinant) Revenue by Application (2027-2032) & (US$ Million) Table 152. China Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units) Table 153. China Hepatitis B Vaccine (Recombinant) Sales by Application (2027-2032) & (W Units) Table 154. China Hepatitis B Vaccine (Recombinant) Sales Price by Application (2021-2026) & (US$/Unit) Table 155. China Hepatitis B Vaccine (Recombinant) Sales Price by Application (2027-2032) & (US$/Unit) Table 156. Asia Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2026) & (US$ Million) Table 157. Asia Hepatitis B Vaccine (Recombinant) Revenue by Type (2027-2032) & (US$ Million) Table 158. Asia Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units) Table 159. Asia Hepatitis B Vaccine (Recombinant) Sales by Type (2027-2032) & (W Units) Table 160. Asia Hepatitis B Vaccine (Recombinant) Sales Price by Type (2021-2026) & (US$/Unit) Table 161. Asia Hepatitis B Vaccine (Recombinant) Sales Price by Type (2027-2032) & (US$/Unit) Table 162. Asia Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2026) & (US$ Million) Table 163. Asia Hepatitis B Vaccine (Recombinant) Revenue by Application (2027-2032) & (US$ Million) Table 164. Asia Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units) Table 165. Asia Hepatitis B Vaccine (Recombinant) Sales by Application (2027-2032) & (W Units) Table 166. Asia Hepatitis B Vaccine (Recombinant) Sales Price by Application (2021-2026) & (US$/Unit) Table 167. Asia Hepatitis B Vaccine (Recombinant) Sales Price by Application (2027-2032) & (US$/Unit) Table 168. Asia Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. Asia Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 170. Asia Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 171. Asia Hepatitis B Vaccine (Recombinant) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 172. Asia Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026) & (W Units) Table 173. Asia Hepatitis B Vaccine (Recombinant) Sales by Country (2027-2032) & (W Units) Table 174. Asia Hepatitis B Vaccine (Recombinant) Sales Price by Country (2021-2026) & (US$/Unit) Table 175. Asia Hepatitis B Vaccine (Recombinant) Sales Price by Country (2027-2032) & (US$/Unit) Table 176. Japan Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 177. South Korea Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 178. India Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 179. Australia Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 180. China Taiwan Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 181. Southeast Asia Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 182. SAMEA Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2026) & (US$ Million) Table 183. SAMEA Hepatitis B Vaccine (Recombinant) Revenue by Type (2027-2032) & (US$ Million) Table 184. SAMEA Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units) Table 185. SAMEA Hepatitis B Vaccine (Recombinant) Sales by Type (2027-2032) & (W Units) Table 186. SAMEA Hepatitis B Vaccine (Recombinant) Sales Price by Type (2021-2026) & (US$/Unit) Table 187. SAMEA Hepatitis B Vaccine (Recombinant) Sales Price by Type (2027-2032) & (US$/Unit) Table 188. SAMEA Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2026) & (US$ Million) Table 189. SAMEA Hepatitis B Vaccine (Recombinant) Revenue by Application (2027-2032) & (US$ Million) Table 190. SAMEA Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units) Table 191. SAMEA Hepatitis B Vaccine (Recombinant) Sales by Application (2027-2032) & (W Units) Table 192. SAMEA Hepatitis B Vaccine (Recombinant) Sales Price by Application (2021-2026) & (US$/Unit) Table 193. SAMEA Hepatitis B Vaccine (Recombinant) Sales Price by Application (2027-2032) & (US$/Unit) Table 194. SAMEA Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. SAMEA Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 196. SAMEA Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 197. SAMEA Hepatitis B Vaccine (Recombinant) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 198. SAMEA Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026) & (W Units) Table 199. SAMEA Hepatitis B Vaccine (Recombinant) Sales by Country (2027-2032) & (W Units) Table 200. SAMEA Hepatitis B Vaccine (Recombinant) Sales Price by Country (2021-2026) & (US$/Unit) Table 201. SAMEA Hepatitis B Vaccine (Recombinant) Sales Price by Country (2027-2032) & (US$/Unit) Table 202. Brazil Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 203. Argentina Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 204. Chile Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 205. Colombia Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 206. Peru Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 207. Saudi Arabia Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 208. Israel Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 209. UAE Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 210. Turkey Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 211. Iran Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 212. Egypt Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Table 213. Key Raw Materials Table 214. Raw Materials Key Suppliers Table 215. Hepatitis B Vaccine (Recombinant) Distributors List Table 216. Hepatitis B Vaccine (Recombinant) Customers List Table 217. Research Programs/Design for This Report Table 218. Authors List of This Report Table 219. Secondary Sources Table 220. Primary Sources List of Figures Figure 1. Hepatitis B Vaccine (Recombinant) Image Figure 2. Global Hepatitis B Vaccine (Recombinant) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatitis B Vaccine (Recombinant) Market Size Share 2021 VS 2025 VS 2032 Figure 4. 10mcg/0.5ml Image Figure 5. 10mcg/ml Image Figure 6. Global Hepatitis B Vaccine (Recombinant) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Hepatitis B Vaccine (Recombinant) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Newborn Image Figure 9. Adult Image Figure 10. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Hepatitis B Vaccine (Recombinant) Revenue (2021-2032) & (US$ Million) Figure 12. Global Hepatitis B Vaccine (Recombinant) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2021-2032) Figure 15. Global Hepatitis B Vaccine (Recombinant) Sales (2021-2032) & (W Units) Figure 16. Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 17. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Hepatitis B Vaccine (Recombinant) Sales YoY (2021-2032) & (W Units) Figure 19. Europe Hepatitis B Vaccine (Recombinant) Sales YoY (2021-2032) & (W Units) Figure 20. China Hepatitis B Vaccine (Recombinant) Sales YoY (2021-2032) & (W Units) Figure 21. Asia (Excluding China) Hepatitis B Vaccine (Recombinant) Sales YoY (2021-2032) & (W Units) Figure 22. South America, Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales YoY (2021-2032) & (W Units) Figure 23. Global Hepatitis B Vaccine (Recombinant) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Hepatitis B Vaccine (Recombinant) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2021-2032) Figure 29. Global Hepatitis B Vaccine (Recombinant) Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 30. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2021-2032) Figure 32. Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2021-2032) Figure 35. Global Hepatitis B Vaccine (Recombinant) Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 36. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2021-2032) Figure 38. North America Hepatitis B Vaccine (Recombinant) Revenue Share by Type (2021-2032) Figure 39. North America Hepatitis B Vaccine (Recombinant) Sales Share by Type (2021-2032) Figure 40. North America Hepatitis B Vaccine (Recombinant) Revenue Share by Application (2021-2032) Figure 41. North America Hepatitis B Vaccine (Recombinant) Sales Share by Application (2021-2032) Figure 42. North America Hepatitis B Vaccine (Recombinant) Revenue Share by Country (2021-2032) Figure 43. North America Hepatitis B Vaccine (Recombinant) Sales Share by Country (2021-2032) Figure 44. Europe Hepatitis B Vaccine (Recombinant) Revenue Share by Type (2021-2032) Figure 45. Europe Hepatitis B Vaccine (Recombinant) Sales Share by Type (2021-2032) Figure 46. Europe Hepatitis B Vaccine (Recombinant) Revenue Share by Application (2021-2032) Figure 47. Europe Hepatitis B Vaccine (Recombinant) Sales Share by Application (2021-2032) Figure 48. Europe Hepatitis B Vaccine (Recombinant) Revenue Share by Country (2021-2032) Figure 49. Europe Hepatitis B Vaccine (Recombinant) Sales Share by Country (2021-2032) Figure 50. China Hepatitis B Vaccine (Recombinant) Revenue Share by Type (2021-2032) Figure 51. China Hepatitis B Vaccine (Recombinant) Sales Share by Type (2021-2032) Figure 52. China Hepatitis B Vaccine (Recombinant) Revenue Share by Application (2021-2032) Figure 53. China Hepatitis B Vaccine (Recombinant) Sales Share by Application (2021-2032) Figure 54. Asia Hepatitis B Vaccine (Recombinant) Revenue Share by Type (2021-2032) Figure 55. Asia Hepatitis B Vaccine (Recombinant) Sales Share by Type (2021-2032) Figure 56. Asia Hepatitis B Vaccine (Recombinant) Revenue Share by Application (2021-2032) Figure 57. Asia Hepatitis B Vaccine (Recombinant) Sales Share by Application (2021-2032) Figure 58. Asia Hepatitis B Vaccine (Recombinant) Revenue Share by Country (2021-2032) Figure 59. Asia Hepatitis B Vaccine (Recombinant) Sales Share by Country (2021-2032) Figure 60. SAMEA Hepatitis B Vaccine (Recombinant) Revenue Share by Type (2021-2032) Figure 61. SAMEA Hepatitis B Vaccine (Recombinant) Sales Share by Type (2021-2032) Figure 62. SAMEA Hepatitis B Vaccine (Recombinant) Revenue Share by Application (2021-2032) Figure 63. SAMEA Hepatitis B Vaccine (Recombinant) Sales Share by Application (2021-2032) Figure 64. SAMEA Hepatitis B Vaccine (Recombinant) Revenue Share by Country (2021-2032) Figure 65. SAMEA Hepatitis B Vaccine (Recombinant) Sales Share by Country (2021-2032) Figure 66. Hepatitis B Vaccine (Recombinant) Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Hepatitis B Vaccine (Recombinant) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 10mcg/0.5ml
  • 10mcg/ml
Applications
  • Newborn
  • Adult
Companies covered
  • GSK
  • Shenzhen Kangtai Biological Products
  • Merck
  • Serum Institute
  • Sanofi Pasteur
  • LG Life Sciences
  • KM Biologics
  • Dynavax Technologies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hepatitis B Vaccine (Recombinant) Market by Type
  3. 1.2.1 Global Hepatitis B Vaccine (Recombinant) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 10mcg/0.5ml
  5. 1.2.3 10mcg/ml
  6. 1.3 Hepatitis B Vaccine (Recombinant) Market by Application
  7. 1.3.1 Global Hepatitis B Vaccine (Recombinant) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Newborn
  9. 1.3.3 Adult
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Hepatitis B Vaccine (Recombinant) Market Dynamics
  1. 2.1 Hepatitis B Vaccine (Recombinant) Industry Trends
  2. 2.2 Hepatitis B Vaccine (Recombinant) Industry Drivers
  3. 2.3 Hepatitis B Vaccine (Recombinant) Industry Opportunities and Challenges
  4. 2.4 Hepatitis B Vaccine (Recombinant) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Hepatitis B Vaccine (Recombinant) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Region
  3. 3.2.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2021-2026)
  5. 3.2.3 Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2027-2032)
  6. 3.2.4 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Hepatitis B Vaccine (Recombinant) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Hepatitis B Vaccine (Recombinant) Sales by Region
  9. 3.4.1 Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Hepatitis B Vaccine (Recombinant) Sales by Region (2021-2026)
  11. 3.4.3 Global Hepatitis B Vaccine (Recombinant) Sales by Region (2027-2032)
  12. 3.4.4 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Manufacturers
  2. 4.1.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Hepatitis B Vaccine (Recombinant) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hepatitis B Vaccine (Recombinant) Sales by Manufacturers
  6. 4.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Hepatitis B Vaccine (Recombinant) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Hepatitis B Vaccine (Recombinant) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Hepatitis B Vaccine (Recombinant) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Hepatitis B Vaccine (Recombinant) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Hepatitis B Vaccine (Recombinant) Manufacturers, Product Type & Application
  13. 4.7 Global Hepatitis B Vaccine (Recombinant) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Hepatitis B Vaccine (Recombinant) Market CR5 and HHI
  16. 4.8.2 2025 Hepatitis B Vaccine (Recombinant) Tier 1, Tier 2, and Tier 3
5 Hepatitis B Vaccine (Recombinant) Market by Type
  1. 5.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Type
  2. 5.1.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Hepatitis B Vaccine (Recombinant) Sales by Type
  6. 5.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Hepatitis B Vaccine (Recombinant) Price by Type
6 Hepatitis B Vaccine (Recombinant) Market by Application
  1. 6.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Application
  2. 6.1.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Hepatitis B Vaccine (Recombinant) Sales by Application
  6. 6.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Hepatitis B Vaccine (Recombinant) Price by Application
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 GSK Hepatitis B Vaccine (Recombinant) Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Shenzhen Kangtai Biological Products
  8. 7.2.1 Shenzhen Kangtai Biological Products Company Information
  9. 7.2.2 Shenzhen Kangtai Biological Products Business Overview
  10. 7.2.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product Portfolio
  12. 7.2.5 Shenzhen Kangtai Biological Products Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck Hepatitis B Vaccine (Recombinant) Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Serum Institute
  20. 7.4.1 Serum Institute Company Information
  21. 7.4.2 Serum Institute Business Overview
  22. 7.4.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Serum Institute Hepatitis B Vaccine (Recombinant) Product Portfolio
  24. 7.4.5 Serum Institute Recent Developments
  25. 7.5 Sanofi Pasteur
  26. 7.5.1 Sanofi Pasteur Company Information
  27. 7.5.2 Sanofi Pasteur Business Overview
  28. 7.5.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product Portfolio
  30. 7.5.5 Sanofi Pasteur Recent Developments
  31. 7.6 LG Life Sciences
  32. 7.6.1 LG Life Sciences Company Information
  33. 7.6.2 LG Life Sciences Business Overview
  34. 7.6.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 LG Life Sciences Hepatitis B Vaccine (Recombinant) Product Portfolio
  36. 7.6.5 LG Life Sciences Recent Developments
  37. 7.7 KM Biologics
  38. 7.7.1 KM Biologics Company Information
  39. 7.7.2 KM Biologics Business Overview
  40. 7.7.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 KM Biologics Hepatitis B Vaccine (Recombinant) Product Portfolio
  42. 7.7.5 KM Biologics Recent Developments
  43. 7.8 Dynavax Technologies
  44. 7.8.1 Dynavax Technologies Company Information
  45. 7.8.2 Dynavax Technologies Business Overview
  46. 7.8.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product Portfolio
  48. 7.8.5 Dynavax Technologies Recent Developments
8 North America
  1. 8.1 North America Hepatitis B Vaccine (Recombinant) Market Size by Type
  2. 8.1.1 North America Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2032)
  3. 8.1.2 North America Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2032)
  4. 8.1.3 North America Hepatitis B Vaccine (Recombinant) Price by Type (2021-2032)
  5. 8.2 North America Hepatitis B Vaccine (Recombinant) Market Size by Application
  6. 8.2.1 North America Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2032)
  7. 8.2.2 North America Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2032)
  8. 8.2.3 North America Hepatitis B Vaccine (Recombinant) Price by Application (2021-2032)
  9. 8.3 North America Hepatitis B Vaccine (Recombinant) Market Size by Country
  10. 8.3.1 North America Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Hepatitis B Vaccine (Recombinant) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Hepatitis B Vaccine (Recombinant) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Hepatitis B Vaccine (Recombinant) Market Size by Type
  2. 9.1.1 Europe Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2032)
  4. 9.1.3 Europe Hepatitis B Vaccine (Recombinant) Price by Type (2021-2032)
  5. 9.2 Europe Hepatitis B Vaccine (Recombinant) Market Size by Application
  6. 9.2.1 Europe Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2032)
  8. 9.2.3 Europe Hepatitis B Vaccine (Recombinant) Price by Application (2021-2032)
  9. 9.3 Europe Hepatitis B Vaccine (Recombinant) Market Size by Country
  10. 9.3.1 Europe Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Hepatitis B Vaccine (Recombinant) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Hepatitis B Vaccine (Recombinant) Market Size by Type
  2. 10.1.1 China Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2032)
  3. 10.1.2 China Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2032)
  4. 10.1.3 China Hepatitis B Vaccine (Recombinant) Price by Type (2021-2032)
  5. 10.2 China Hepatitis B Vaccine (Recombinant) Market Size by Application
  6. 10.2.1 China Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2032)
  7. 10.2.2 China Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2032)
  8. 10.2.3 China Hepatitis B Vaccine (Recombinant) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hepatitis B Vaccine (Recombinant) Market Size by Type
  2. 11.1.1 Asia Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2032)
  4. 11.1.3 Asia Hepatitis B Vaccine (Recombinant) Price by Type (2021-2032)
  5. 11.2 Asia Hepatitis B Vaccine (Recombinant) Market Size by Application
  6. 11.2.1 Asia Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2032)
  8. 11.2.3 Asia Hepatitis B Vaccine (Recombinant) Price by Application (2021-2032)
  9. 11.3 Asia Hepatitis B Vaccine (Recombinant) Market Size by Country
  10. 11.3.1 Asia Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Hepatitis B Vaccine (Recombinant) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Hepatitis B Vaccine (Recombinant) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hepatitis B Vaccine (Recombinant) Market Size by Type
  2. 12.1.1 SAMEA Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Hepatitis B Vaccine (Recombinant) Price by Type (2021-2032)
  5. 12.2 SAMEA Hepatitis B Vaccine (Recombinant) Market Size by Application
  6. 12.2.1 SAMEA Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Hepatitis B Vaccine (Recombinant) Price by Application (2021-2032)
  9. 12.3 SAMEA Hepatitis B Vaccine (Recombinant) Market Size by Country
  10. 12.3.1 SAMEA Hepatitis B Vaccine (Recombinant) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Hepatitis B Vaccine (Recombinant) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Hepatitis B Vaccine (Recombinant) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Hepatitis B Vaccine (Recombinant) Value Chain Analysis
  2. 13.1.1 Hepatitis B Vaccine (Recombinant) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Hepatitis B Vaccine (Recombinant) Production Mode & Process
  6. 13.2 Hepatitis B Vaccine (Recombinant) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Hepatitis B Vaccine (Recombinant) Distributors
  9. 13.2.3 Hepatitis B Vaccine (Recombinant) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst